Alpha-synuclein Seed Amplification Assay Program

Ends on 13 September 2021

This program supports research that will facilitate integration of alpha-synuclein seed amplification assays into clinical studies for the purposes of predicting prognosis, tracking disease progression and monitoring therapeutic response.